Segment and Related Information (Tables)

9 Months Ended

Mar. 31, 2014

Segment Revenue and Operating Income (Loss)

Segment revenue and operating income (loss) were as follows during the periods presented:


(In thousands)	Research			Molecular diagnostics		Companion diagnostics			Total
Three months ended March 31, 2014:
Revenue	$	—			176,191		6,733		$	182,924
Depreciation and amortization		502			2,506		471			3,479
Segment operating income (loss)		(15,455	)		70,815		(73	)		55,287
Three months ended March 31, 2013:
Revenue	$	—			148,384		8,088		$	156,472
Depreciation and amortization		1,210			2,424		821			4,455
Segment operating income (loss)		(17,224	)		76,165		(1,023	)		57,918
Nine months ended March 31, 2014:
Revenue	$	—			565,335		24,115		$	589,450
Depreciation and amortization		1,494			5,335		1,462			8,291
Segment operating income (loss)		(48,422	)		266,794		2,816			221,188
Nine months ended March 31, 2013:
Revenue	$	—			416,304		22,746		$	439,050
Depreciation and amortization		1,818			3,543		1,274			6,635
Segment operating income (loss)		(47,989	)		214,195		(4,120	)		162,086


	Three months ended						Nine months ended
	March 31,						March 31,
(In thousands)	2014			2013			2014			2013
Total operating income for reportable segments	$	55,287		$	57,918		$	221,188		$	162,086
Interest income		2,498			1,434			5,190			4,187
Other		(442	)		(111	)		(1,066	)		(224	)
Income tax provision		20,573			21,349			82,719			62,984

Net income	$	36,770		$	37,892		$	142,593		$	103,065

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References+ Details